Japan Favors 'Bio-betters' Over Biosimilars
This article was originally published in PharmAsia News
Executive Summary
Takao Hayakawa of Japan's Pharmaceuticals and Medical Devices Agency recently laid out the philosophy Japan has taken toward biosimilars in its March 2009 guidelines
You may also be interested in...
One Year After Japan Paves Way, Follow-on Biologics Start Blossoming
Japan's Ministry of Health, Labor and Welfare has seen an influx of companies interested in bringing products to Japan since releasing official guidelines for biosimilars last March
One Year After Japan Paves Way, Follow-on Biologics Start Blossoming
Japan's Ministry of Health, Labor and Welfare has seen an influx of companies interested in bringing products to Japan since releasing official guidelines for biosimilars last March
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan